Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cody J Peer

Showing results (121-130 of 140) with videos related to

Pageof 14
Sort By:
Blood Advances|May 27, 2026
Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 studyNoa G Holtzman, Annie Im, Lauren M Curtis, et al.
Journal for Immunotherapy of Cancer|November 20, 2021
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumorsKevin Conlon, Dionysios C Watson, Thomas A Waldmann, et al.
Molecular Cancer Research : MCR|April 9, 2017
Differential Expression of OATP1B3 Mediates Unconjugated Testosterone InfluxTristan M Sissung, Ariel M Ley, Jonathan D Strope, et al.
Journal of Neuro-Oncology|October 11, 2020
A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomasSean J Hipp, Stewart Goldman, Aradhana Kaushal, et al.
Nature Communications|July 15, 2018
Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastasesBrunilde Gril, Anurag N Paranjape, Stephan Woditschka, et al.
Cancers|August 26, 2023
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric RhabdomyosarcomaJerry T Wu, Adam Cheuk, Kristine Isanogle, et al.
Blood|September 25, 2020
A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host diseaseLauren M Curtis, Alen Ostojic, David J Venzon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2023
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain MetastasesSarah Jenkins, Wei Zhang, Seth M Steinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2014
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasmsBeata Holkova, Maciej Kmieciak, E Brent Perkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancerKevin C Conlon, Enrico Lugli, Hugh C Welles, et al.
Pageof 14

Showing results (121-130 of 140) with videos related to

Sort By:
Pageof 14
Blood Advances|May 27, 2026
Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 studyNoa G Holtzman, Annie Im, Lauren M Curtis, et al.
Journal for Immunotherapy of Cancer|November 20, 2021
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumorsKevin Conlon, Dionysios C Watson, Thomas A Waldmann, et al.
Molecular Cancer Research : MCR|April 9, 2017
Differential Expression of OATP1B3 Mediates Unconjugated Testosterone InfluxTristan M Sissung, Ariel M Ley, Jonathan D Strope, et al.
Journal of Neuro-Oncology|October 11, 2020
A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomasSean J Hipp, Stewart Goldman, Aradhana Kaushal, et al.
Nature Communications|July 15, 2018
Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastasesBrunilde Gril, Anurag N Paranjape, Stephan Woditschka, et al.
Cancers|August 26, 2023
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric RhabdomyosarcomaJerry T Wu, Adam Cheuk, Kristine Isanogle, et al.
Blood|September 25, 2020
A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host diseaseLauren M Curtis, Alen Ostojic, David J Venzon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2023
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain MetastasesSarah Jenkins, Wei Zhang, Seth M Steinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2014
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasmsBeata Holkova, Maciej Kmieciak, E Brent Perkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancerKevin C Conlon, Enrico Lugli, Hugh C Welles, et al.
Pageof 14